Biogen Idec initiated with "buy"

09.03.10 - Soleil Securities Group

NEW YORK, March 9 (newratings.com) - Analysts at Soleil Securities Group               initiate coverage of Biogen Idec Inc (BIIB) with a "buy" rating. The target price is set to $70.